Biotech Fundraising and Trial Setbacks
Kilder
- BioPharma Dive: This week in charts: Biotech’s rebound is undeniable
- Endpoints: BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
- Fierce Biotech: BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test - Fierce Biotech
- Reuters: BioNTech halts mRNA colorectal cancer vaccine trial after safety review - Reuters
- Barron's: BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win - Barron's
- Labiotech: Six MASH biotech companies shaping the future of liver disease treatment
- GEN: CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial
- GEN: Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T - Genetic Engineering and Biotechnology News
- STAT: STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
- STAT: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs - STAT
- BioPharma Dive: Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
- Finance: Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines - Yahoo Finance
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.